Home › Chronic Myeloid Leukemia › Georgia › Augusta
Chronic Myeloid Leukemia clinical trials in Augusta, GA
4 studies for Chronic Myeloid Leukemia are looking for participants at sites in and around Augusta (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Study of Olverembatinib (HQP1351) in Patients With CML-CP
RecruitingPhase 3
- Ascentage Investigative Site #1045, Augusta
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
RecruitingObservational study
- Georgia Cancer Center at Augusta University Health, Augusta
A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia (CARDINAL)
RecruitingPhase 1/2
- Georgia Cancer Center at Augusta University, Augusta
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
RecruitingPhase 1
- Augusta Cancer Center, Augusta
About Chronic Myeloid Leukemia
Chronic myeloid leukemia (CML) is a cancer of the white blood cells. It usually affects older adults. Learn about symptoms, genetics, and treatment.
More about Chronic Myeloid Leukemia on MedlinePlus
Chronic Myeloid Leukemia trials in other cities
- Houston, TX18 studies
- Seattle, WA11 studies
- New York City, NY11 studies
- Birmingham, AL6 studies
- Detroit, MI6 studies
- Chicago, IL6 studies
- Portland, OR6 studies
- Philadelphia, PA6 studies
- Baldwin Park, CA6 studies
- Nashville, TN5 studies
- Columbus, OH5 studies
- Boston, MA5 studies
Other studies in Augusta
- Acute Myeloid Leukemia10 studies
- Ovarian Cancer8 studies
- Endometrial Cancer7 studies
- Cancer (all types)7 studies
- Sickle Cell Disease5 studies
- Breast Cancer5 studies
- Myasthenia Gravis4 studies
- Blood Cancers4 studies
- Burkitt Lymphoma4 studies
- Diffuse Large B-Cell Lymphoma4 studies
- Non-Hodgkin Lymphoma4 studies
- Cervical Cancer4 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.